Navigation Links
FDA Accepts Immucor's Response to Warning Letter
Date:6/6/2008

NORCROSS, Ga., June 6 /PRNewswire-FirstCall/ -- Immucor, Inc., (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, announced that today the FDA notified the company that it has reviewed Immucor's response to the previously-reported warning letter, and Immucor's proposed corrective actions appear to be adequate. The FDA stated it would evaluate the implementation and effectiveness of those corrective actions, as well as Immucor's overall compliance, at its next inspection.

The warning letter, which related to Immucor's internal quality system, was dated May 2, 2008, and the company responded on May 22, 2008, detailing the corrective actions it proposed to take.

Immucor CEO Dr. Gioacchino De Chirico said: "We take our regulatory responsibilities very seriously and worked diligently to respond to the FDA. We are pleased the FDA accepted our action plan, and was willing to move as quickly as it did. We have already begun implementing the plan."

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments.

For more information on Immucor, please visit our website at http://www.immucor.com .

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "may," "will,
'/>"/>

SOURCE Immucor, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
2. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
3. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
4. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
5. FDA Accepts Ranexa(R) sNDA and NDA for Filing
6. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
7. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
8. Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkins Lymphoma
9. Oncolytics Biotech Inc. Announces Publication of Research on Immune Response to REOLYSIN(R) during a Phase I Clinical Trial
10. MannKind Corporation Response to Recent Market Events
11. Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... 2 Nearly 600 medical r... funders today convened to explore novel developme... the inaugural Partnering for Cures meeting. ,...the Milken Institute, convened Partnering for Cur...ed to turn a scientific discovery into an accessib...
(Date:12/2/2009)..., Gabon, December 2 , - "...lem and Heritage" , Coinciding with the I...he,Gabonese Republic is hosting an international c...feguarding biological resources in Africa. The,con...eaders, ministers,scientific experts, private com...
(Date:12/2/2009)..., Dec. 2 S*BIO Pte Ltd today annou...ibitor, SB1518, at The American Society of Hematol...ans. ,, Data will be presented on the clinical ...SB1518 detailing its safety, tolerability and phar...e levels ranging from 100 to 600 mg. These doses w...
(Date:12/2/2009)..., Dec. 2 /PRNewswire-Asia/ -- The world is going t... and uncertainty is part of many,businesses and in...s been,relatively immune to the economic downturn,... During the midst of the difficult times this ye... inaugurated an R&D center in Shanghai, the la...
Breaking Biology Technology:Medical Research Leaders Explore Novel Strategies to Expedite the Search for Cures 2Libreville International Conference 2-3 June 2010 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
...e quantities of difficult-to-express proteins ,...iochemical & Molecular Allergology, Research Cente...odonPlus(DE3)-RIL cells * with,extra copies of E...ossible to attain high-level expression of difficu...nduced expression of several recombinant peanut al...
...RoboCycler Gradient 96 temperature cycler ,,.... , Stratagenes RoboCycler Gradient 96 tempera...ed to perform fluorescent-tag cycle,sequencing u...ing,ready reaction kit. The new Hot Top Assembly...ays that hinder the loading of cycle sequencing re...
...,, Achieve superior transfection efficiencie...cott Basehore Jeff Braman ,Stratagene , Plasm...,EF plasmid midiprep kit, a kit based on anion e...um chloride density gradient centrifugation. Plasm...-nm optical density ratios) were comparable,with...
Other Biology Technology:High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 2High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 3High-Level Expression of Peanut Allergens Affected by Rare Codon Usage 4Automated Fluorescent-Tag Cycle Sequencing 2Automated Fluorescent-Tag Cycle Sequencing 3Automated Fluorescent-Tag Cycle Sequencing 4Automated Fluorescent-Tag Cycle Sequencing 5Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 2Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 3Highest Transfection Efficiency of an Endotoxin-Sensitive Mammalian Cell,Line 4
(Date:12/3/2009)...design of the upcoming forest deal at Copenhagen i...to a scientist at the University of Leeds. , Wr...t at least 50% of the carbon credit payments to be...ssions from Deforestation and Degredation), should...operty rights assured. , "There is the potential...
(Date:12/3/2009)... U.S. Department of Energy,s (DOE) Brookhaven Nati...n Institute of Science has made a major step in un...mation in DNA that is necessary to carry out impor... in the December 1, 2009 edition of Nature Struct...eins responsible for interacting at specific sites...
(Date:12/2/2009)...no men have a more difficult time quitting smoking...ure, but acculturation has no affect on Latinas od...are published in Cancer Epidemiology, Biomarkers ...on for Cancer Research. The December issue has a s...s smoking cessation differently for Latino men and...
Breaking Biology News(10 mins):Forest deal at Copenhagen must avoid creating 'carbon refugees' 2Grooving down the helix 2Grooving down the helix 3Acculturation affects smoking cessation success among Latinos 2A Pets Bite Can Pass on MRSA 49599 1A Pets Bite Can Pass on MRSA 49599 2Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 1Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 2Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 3Spinal Cancer Patient Finds New Hope at the Palo Alto Medical Foundation 49594 4HealthLeaders InterStudy Unveils Enhanced Employer Vantage 49589 1HealthLeaders InterStudy Unveils Enhanced Employer Vantage 49589 2
... desperately try to reach for a break in the canop... affliction: Shade avoidance syndrome or SAS. Now,... light by researchers at the Salk Institute for Bi...rs shade, plants switch on a natural chemical fact...auxin that lets a plant grow and ultimately stretc...
...the inaugural conference of the iPlant Collaborati... virtual center in cyberspace for plant sciences r...itled "Bringing Plant and Computing Scientists Tog...nd scheduled for April 7-9, 2008, will take the fi...test unsolved mysteries its grand challenge quest...
... Society of Agronomy (ASA), Crop Science Society o...ica (SSSA) recognize the following undergraduate s... National Student Recognition Program announced in...ine. , The 2008 National Student Recognition Prog...s enrolled in agronomy, crop, soil, or environment...
Other Biology News:A place in the sun 2A place in the sun 3iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 2iPlant Kickoff Conference at CSHL begins tackling plant biology's grand challenges 3Outstanding undergraduates recognized in agronomy, crop, soil, and environmental sciences 2
...noCortin (POMC) has long been a molecule of fascin... of biologically-active peptides such as ACTH, -Li...mulating Hormone (a-MSH) and more. It is also a ve...rtebrates studied, including those "living fossils...
Mouse Anti-Rat Pan-NMDA NR1 Monoclonal Antibody, Unconjugated, Clone R1JHL from Calbiochem
BRASMC (B950-05) from European Collection of Cell Cultures (ECACC)
T4 DNA Ligase from Promega
Biology Products: